Ionis Pharmaceuticals, Inc. Income (Loss) from Equity Method Investments
Ionis Pharmaceuticals, Inc. (IONS) reported Income (Loss) from Equity Method Investments of $0 for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-02.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2015-03-02
- Ionis Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2012-12-31 was -$267.00K.
- Ionis Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2012-09-30 was $0.00.
- Ionis Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2012-06-30 was -$163.00K.
- Ionis Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2012-03-31 was -$976.00K.
- Ionis Pharmaceuticals, Inc. income (loss) from equity method investments for fiscal 2014 was $0.00.
- Ionis Pharmaceuticals, Inc. income (loss) from equity method investments for fiscal 2013 was $0.00.
- Ionis Pharmaceuticals, Inc. income (loss) from equity method investments for fiscal 2012 was -$1.41M.
- Ionis Pharmaceuticals, Inc. income (loss) from equity method investments for fiscal 2011 was -$3.55M.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month | Income (Loss) from Equity Method Investments 12 month as first filed |
|---|---|---|---|---|---|
| 2014-12-31 | $0.00 10-K · filed 2015-03-02 | ||||
| 2013-12-31 | $0.00 10-K · filed 2015-03-02 | ||||
| 2012-12-31 | -$267.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -$267.00K derived: sum of 2 quarters · filed 2015-03-02 | -$430.00K derived: sum of 3 quarters · filed 2015-03-02 | -$1.41M 10-K · filed 2015-03-02 | |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | -$163.00K derived: sum of 2 quarters · filed 2013-11-05 | -$1.14M 10-Q · filed 2013-11-05 | -$2.42M derived: sum of 4 quarters · filed 2014-03-03 | |
| 2012-06-30 | -$163.00K 10-Q · filed 2013-08-06 | -$1.14M 10-Q · filed 2013-08-06 | -$2.42M derived: sum of 3 quarters · filed 2014-03-03 | -$2.80M derived: sum of 4 quarters · filed 2014-03-03 | |
| 2012-03-31 | -$976.00K 10-Q · filed 2013-05-07 | -$2.25M derived: sum of 2 quarters · filed 2014-03-03 | -$2.64M derived: sum of 3 quarters · filed 2014-03-03 | -$3.67M derived: sum of 4 quarters · filed 2014-03-03 | |
| 2011-12-31 | -$1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | -$1.67M derived: sum of 2 quarters · filed 2014-03-03 | -$2.70M derived: sum of 3 quarters · filed 2014-03-03 | -$3.55M 10-K · filed 2014-03-03 | |
| 2011-09-30 | -$386.00K 10-Q · filed 2012-11-06 | -$1.42M derived: sum of 2 quarters · filed 2012-11-06 | -$2.27M 10-Q · filed 2012-11-06 | -$2.80M derived: sum of 4 quarters · filed 2013-02-28 | |
| 2011-06-30 | -$1.03M 10-Q · filed 2012-08-06 | -$1.89M 10-Q · filed 2012-08-06 | -$2.41M derived: sum of 3 quarters · filed 2013-02-28 | -$3.34M derived: sum of 4 quarters · filed 2013-02-28 | |
| 2011-03-31 | -$856.00K 10-Q · filed 2012-05-09 | -$1.38M derived: sum of 2 quarters · filed 2013-02-28 | -$2.31M derived: sum of 3 quarters · filed 2013-02-28 | -$6.25M derived: sum of 4 quarters · filed 2013-02-28 | |
| 2010-12-31 | -$521.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | -$1.45M derived: sum of 2 quarters · filed 2013-02-28 | -$5.39M derived: sum of 3 quarters · filed 2013-02-28 | -$6.88M 10-K · filed 2013-02-28 | -$2.23M 10-K · filed 2011-03-01 |
| 2010-09-30 | -$930.00K 10-Q · filed 2011-11-08 | -$4.87M derived: sum of 2 quarters · filed 2011-11-08 | -$6.36M 10-Q · filed 2011-11-08 | ||
| 2010-06-30 | -$3.94M 10-Q · filed 2011-08-08 | -$5.43M 10-Q · filed 2011-08-08 | |||
| 2010-03-31 | -$1.49M 10-Q · filed 2011-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |